Furthermore, we found that treatment with RIPK1 inhibitor, Nec-1 significantly inhibited the activation of the RIPK1/RIPK3/MLKL signaling pathway, ameliorated renal dysfunction, and reduced kidney inflammation and renal fibrosis. Here, MLKL is linked to renal fibrosis.